Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Gastrointestinal 1

Conditions

Breast Neoplasms 484Triple Negative Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms, Male 22Neoplasms 20Inflammatory Breast Neoplasms 20Neoplasm Metastasis 19Prostatic Neoplasms 17HER2-positive Breast Cancer 16Ovarian Neoplasms 13Lung Neoplasms 13Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 9Melanoma 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Neutropenia 6Breast Diseases 6Sarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Primary Breast Cancer 4Pathologic Complete Response 4Endometrial Neoplasms 4

Interventions

Trastuzumab 5Carboplatin 5Docetaxel 4pertuzumab 3Paclitaxel 3Cyclophosphamide 3pembrolizumab 2Epirubicin 2Doxorubicin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1taxane 1talazoparib 1sarilumab 1pyrotinib 1pirarubicin 1pexidartinib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1durvalumab 1dostarlimab 1cemiplimab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pathologic Complete Response × Docetaxel × Breast × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT00636441 2015-12-11

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Duke University

Phase 2 Terminated
56 enrolled 16 charts
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

307 Hospital of PLA

Phase 3 Completed
104 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡